Teva study reveals diagnostic gap in tardive dyskinesia among young adults
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
May 18, 2026 8:01 AM EDTNew analysis from the IMPACT-TD Registry confirms tardive dyskinesia (TD) causes a significant burden for most individuals with concomitant mood disorders, impacting their lives regardless of ageThe data shows that 85% of young adults with mood disorders living with TD movements, ages 18-29 (n=13), experience moderate to severe TD impact, yet only 23% received a formal diagnosis of TD, revealing a gap in disease identificationTeva is dedicated to advancing research and initiatives that deepen clinical understanding, identify diagnostic gaps and improve outcomes for patients with... More
